Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSC vs BAT in Steroid Refractory Acute GvHD
NCT04118556Phase 2Terminated
- Start
- Dec 2021
- Primary completion
- Apr 2026
- Modality
- Mesenchymal Stem Cells
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of decidua stromal cells in Acute Graft-Versus-Host Disease (aGvHD) (2 arms). Primary endpoints: Safety and tolerability evaluation including Severe Adverse Events (SAE) at 5 years and Durable Overall Response at 56 days. Started Dec 2021; status: terminated.
02
Drugs
decidua stromal cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04118556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118556.